A Process for Evaluating Quality Decision-Making Practices During the Development, Review and Reimbursement of Medicines.
Health Technology Assessment
Medicines Development
QoDoS
Quality Decision-Making
Regulatory Review
Journal
International journal of health policy and management
ISSN: 2322-5939
Titre abrégé: Int J Health Policy Manag
Pays: Iran
ID NLM: 101619905
Informations de publication
Date de publication:
01 Feb 2022
01 Feb 2022
Historique:
received:
02
01
2020
accepted:
30
05
2020
pubmed:
3
7
2020
medline:
26
3
2022
entrez:
3
7
2020
Statut:
epublish
Résumé
The development of a medicine is not only underpinned by good science but also by Quality DecisionMaking Practices (QDMPs). Indeed, it is important to ensure that all organisations involved in the lifecycle of medicines are aligning their practices in decision-making to the QDMPs to ensure quality, transparent and consistent decisionmaking processes. The aim of this study was to evaluate the practicality of QoDoS (Quality of Decision-Making Orientation Scheme) in assessing the incorporation of ten QDMPs during the development, review and reimbursement of medicines, illustrated by case studies with a pharmaceutical company, a regulatory authority and a health technology assessment (HTA) agency. Individuals from each organisation completed the 47-item QoDoS questionnaire. The results demonstrate the applicability of QoDoS in identifying favourable and unfavourable practices and in assessing the consistency and transparency of the QDMPs within each organisation, as well as across the different stakeholders. Furthermore, the study established the value of the methodology in raising awareness of the biases and best practices in decision-making, as well as having a basis for discussion for differences within and across stakeholders to promote consistency and alignment in decision-making. Finally, the QoDoS demonstrated the need for improvement across a number of decision-making practices for the 3 organisations such as the evaluation of alternatives and of the decision impact. The QoDoS can be used to benchmark organisations' decision-making practices to provide a basis for discussion to ultimately encourage a level of trust across and within organisations and helping to identify areas for improvement.
Sections du résumé
BACKGROUND
BACKGROUND
The development of a medicine is not only underpinned by good science but also by Quality DecisionMaking Practices (QDMPs). Indeed, it is important to ensure that all organisations involved in the lifecycle of medicines are aligning their practices in decision-making to the QDMPs to ensure quality, transparent and consistent decisionmaking processes.
METHODS
METHODS
The aim of this study was to evaluate the practicality of QoDoS (Quality of Decision-Making Orientation Scheme) in assessing the incorporation of ten QDMPs during the development, review and reimbursement of medicines, illustrated by case studies with a pharmaceutical company, a regulatory authority and a health technology assessment (HTA) agency. Individuals from each organisation completed the 47-item QoDoS questionnaire.
RESULTS
RESULTS
The results demonstrate the applicability of QoDoS in identifying favourable and unfavourable practices and in assessing the consistency and transparency of the QDMPs within each organisation, as well as across the different stakeholders. Furthermore, the study established the value of the methodology in raising awareness of the biases and best practices in decision-making, as well as having a basis for discussion for differences within and across stakeholders to promote consistency and alignment in decision-making. Finally, the QoDoS demonstrated the need for improvement across a number of decision-making practices for the 3 organisations such as the evaluation of alternatives and of the decision impact.
CONCLUSION
CONCLUSIONS
The QoDoS can be used to benchmark organisations' decision-making practices to provide a basis for discussion to ultimately encourage a level of trust across and within organisations and helping to identify areas for improvement.
Identifiants
pubmed: 32610811
doi: 10.34172/ijhpm.2020.86
pmc: PMC9278608
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
128-137Informations de copyright
© 2022 The Author(s); Published by Kerman University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Références
Pharmacoepidemiol Drug Saf. 2015 Mar;24(3):319-28
pubmed: 25628072
Value Health. 2018 Jun;21(6):707-714
pubmed: 29909876
Front Pharmacol. 2016 Jul 13;7:180
pubmed: 27468267
Front Pharmacol. 2019 Jan 23;10:17
pubmed: 30728777
Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):1004-12
pubmed: 23740622
Front Pharmacol. 2017 Apr 10;8:189
pubmed: 28443022
Nat Rev Drug Discov. 2015 Jul;14(7):455-6
pubmed: 26065405
Clin Pharmacol Ther. 2019 Apr;105(4):935-942
pubmed: 30472729
Ther Innov Regul Sci. 2017 Mar;51(2):250-256
pubmed: 30231720